8-K: Emmaus Life Sciences Restructures $3M Debt

Emmaus Life Sciences exchanged an outstanding $3 million convertible note for new common stock and a $600,000 convertible promissory note.

Summary

• Emmaus Life Sciences, Inc. (the "Company") entered into an Exchange Agreement with Dong Seon Kim (the "Investor") on December 17, 2025.
• The Company surrendered an existing convertible promissory note (the "Subject Note") with a principal amount of $3,000,000, which bore 10% annual interest and was convertible at $0.13 per share.
• In exchange, the Investor received 6,332,692 shares of common stock, valued at approximately $0.38 per share, and a new convertible promissory note (the "Exchange Note") with a principal amount of $600,000.
• The new Exchange Note bears an annual interest rate of 10%, payable semi-annually, increasing to 12% upon initial repayment failure after six months.
• The initial conversion price for the Exchange Note is $0.01 per share, subject to quarterly adjustment to the Average VWAP if lower.
• The Exchange Securities were issued without additional consideration, relying on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
• The new Exchange Note is senior in right of payment to all other Company indebtedness.

Sentiment

Score: 3

Explanation: The debt restructuring, while addressing an immediate $3 million obligation, comes at a significant cost to existing shareholders through substantial dilution. The issuance of over 6.3 million shares and a new convertible note with an extremely low initial conversion price of $0.01 suggests a distressed valuation and high future dilution potential. The 'due on demand' nature of the new note and the potential for an increased interest rate upon repayment failure highlight ongoing financial risks. These factors, combined with restrictive covenants and numerous Event of Default triggers, point to a challenging financial outlook and significant downside risk for current equity holders.

Positives

• Successfully restructured an existing $3,000,000 debt obligation, converting a significant portion into equity.
• The new convertible note has a lower principal amount ($600,000) compared to the original note, reducing the immediate debt burden.
• The issuance of common stock at $0.38 per share for a portion of the debt indicates a valuation for that part of the exchange.
• The new note's initial conversion price of $0.01 is significantly lower than the previous note's $0.13, which could incentivize conversion and further debt reduction through equity.

Negatives

• The company issued a substantial number of shares (6,332,692) as part of the exchange, which could lead to significant shareholder dilution.
• The new convertible note still represents a financial obligation that is due on demand by the holder, creating potential liquidity risk.
• The interest rate on the new note can automatically increase from 10% to 12% upon initial repayment failure after six months, indicating potential financial stress if not managed.
• The initial conversion price of $0.01 for the new note is very low, suggesting a potentially low market valuation of the company's stock at the time of the agreement or a highly dilutive conversion mechanism.

Risks

• Dilution Risk: The issuance of 6,332,692 shares of common stock and the potential conversion of the $600,000 Exchange Note at a low conversion price ($0.01 initially) could significantly dilute existing shareholders.
• Repayment Risk: The Exchange Note is "due and payable on demand" by the Holder, creating a liquidity risk for the Company if the Holder demands repayment.
• Increased Interest Rate Risk: If the Company fails to make an initial repayment after six months, the interest rate on the Exchange Note automatically increases from 10% to 12%, increasing debt servicing costs.
• Operational Covenants: The Company is subject to various covenants, including restrictions on liens, investments, dispositions, charter amendments, mergers, equity repurchases, and affiliate transactions, which could limit operational flexibility.
• Event of Default Triggers: A wide range of events, including payment defaults, covenant breaches, delisting, trading suspensions, failure to deliver conversion shares, large judgments (over $500,000), executive officer indictment/conviction for certain violations, and significant adverse regulatory actions (e.g., FDA recalls, warning letters, settlements over $1,000,000), can trigger an Event of Default, leading to immediate acceleration of the note.
• Regulatory Risk: Significant enforcement actions, warning letters, or mandated recalls by the U.S. Food and Drug Administration or other Governmental Authorities could have a Material Adverse Effect and trigger an Event of Default.
• Market Listing Risk: Suspension from trading or delisting from the Principal Market for certain periods constitutes an Event of Default.

Future Outlook

The filing outlines the terms of a debt restructuring, but does not provide explicit forward-looking statements or guidance regarding future financial performance, operational plans, or market expectations beyond the terms of the new note.

Management Comments

• "The Company covenants and agrees that it will honor all Notices of Conversion tendered by the Holder at any time, and from the time, after the delivery of the Repayment Notice through the date all amounts owing thereon are due and paid in full."
• "The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation or bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and will at all times in good faith carry out all of the provisions of this Note and take all action as may be required to protect the rights of the Holder of this Note."

Industry Context

This filing details a specific debt restructuring event for Emmaus Life Sciences and does not provide information to analyze broader industry trends or competitors.

Corporate Governance

Related Party Transactions

• The Exchange Agreement is between Emmaus Life Sciences, Inc. and Dong Seon Kim, who is the "Original Holder" of the Subject Note and the recipient of the Exchange Securities. This transaction involves a significant investor and the company.

Stakeholder Impact

• Shareholders: Existing shareholders face significant dilution due to the issuance of 6,332,692 shares of common stock and the potential for further dilution from the conversion of the new $600,000 note at a low initial conversion price of $0.01.
• Creditors (other than the Holder): The new Exchange Note is senior or higher priority in right of payment to all other Indebtedness of the Company, potentially subordinating other creditors.
• Company Management: Management is bound by various covenants and restrictions, limiting flexibility in certain corporate actions (e.g., mergers, asset dispositions, charter amendments) without the note holder's consent.
• Company Operations: The requirement to maintain insurance and the potential for an Event of Default triggered by significant regulatory actions (FDA recalls, warning letters, large settlements) could impact operational stability and focus.

Next Steps

• The Company must ensure it has sufficient authorized and unissued common stock to satisfy conversion obligations for the new note, potentially requiring stockholder approval for an increase in authorized shares within 75 days of an Authorized Share Failure.
• The Company must adhere to various covenants outlined in the Exchange Note, including restrictions on liens, investments, dispositions, and corporate actions.
• The Company must maintain insurance as required by the note.

Key Dates

Recommendation

The debt restructuring, while addressing an immediate $3 million obligation, comes at a significant cost to existing shareholders through substantial dilution. The issuance of over 6.3 million shares and a new convertible note with an extremely low initial conversion price of $0.01 suggests a distressed valuation and high future dilution potential. The "due on demand" nature of the new note introduces considerable liquidity risk, and the potential for an increased interest rate upon repayment failure indicates ongoing financial fragility. These factors, combined with restrictive covenants and numerous Event of Default triggers, point to a challenging financial outlook and significant downside risk for current equity holders.

Keywords

Emmaus Life Sciences, Convertible Promissory Note, Debt Restructuring, SEC Filing, Form 8-K, Exchange Agreement, Common Stock, Share Dilution, Corporate Finance, Securities Act Section 3(a)(9), Financial Obligation, Corporate Governance, Risk Factors